VECTORS
20180171354 ยท 2018-06-21
Assignee
Inventors
Cpc classification
C12N2310/20
CHEMISTRY; METALLURGY
C12N9/22
CHEMISTRY; METALLURGY
C12N2800/80
CHEMISTRY; METALLURGY
C12N15/11
CHEMISTRY; METALLURGY
C12N15/113
CHEMISTRY; METALLURGY
A61K48/00
HUMAN NECESSITIES
C12P19/34
CHEMISTRY; METALLURGY
C12N15/63
CHEMISTRY; METALLURGY
C12N2830/42
CHEMISTRY; METALLURGY
C12N9/96
CHEMISTRY; METALLURGY
C12N15/67
CHEMISTRY; METALLURGY
C12N2840/445
CHEMISTRY; METALLURGY
C12N2810/10
CHEMISTRY; METALLURGY
International classification
C12N15/113
CHEMISTRY; METALLURGY
C12P19/34
CHEMISTRY; METALLURGY
C12N15/11
CHEMISTRY; METALLURGY
C12N9/22
CHEMISTRY; METALLURGY
C12N15/67
CHEMISTRY; METALLURGY
Abstract
We disclose dumbbell-shaped vectors adapted for efficient expression in mammalian cells. We also disclose a novel method allowing the efficient synthesis of dumbbell-shaped vectors at low cost for delivery of recombinant DNA and RNA into host cells; and the use of dumbbell-shaped vectors for transient expression in, for example, primary human cells.
Claims
1.-35. (canceled)
36. A dumbbell-shaped expression vector wherein said vector comprises: i) one or more linear or hairpin-shaped transcription cassettes each comprising a nucleotide sequence encoding a nucleic acid molecule to be expressed; ii) a nucleotide sequence comprising a DNA nuclear targeting sequence; iii) a nucleotide sequence comprising an enhancer nucleotide sequence and optionally at least one intron associated with said enhancer nucleotide sequence to enhance expression of said expressed nucleic acid molecule; iv) a nucleotide sequence comprising a post-transcriptional regulatory element or a constitutive nuclear transport element; and v) a nucleotide sequence comprising a sequence with homology to a part of a mammalian genome that can serve as repair template which is either single or double stranded for RNA-guided genome editing.
37. The vector according to of claim 36 wherein the one or more linear or hairpin-shaped transcription cassettes each comprising a nucleotide sequence encoding a nucleic acid molecule to be expressed is linked to a minimal transcription promoter nucleotide sequence.
38. The vector according to claim 37 wherein said minimal transcription promoter sequence further comprises a transcription termination nucleotide sequence wherein transcription initiation and termination nucleotide sequences are operatively coupled.
39. The vector according to claim 36 wherein said vector comprises at least one internal loop domain.
40. The vector according to claim 39 wherein said loop domain comprises an abasic site or nucleotide mismatch.
41. The vector according to claim 40 wherein said abasic site comprises one or more apurinic/apyrimidinic abasic sites.
42. The vector according to 40 wherein said nucleotide mismatch comprises a tetrahydrofuran-based mimic of an abasic site.
43. The vector according to 36 wherein said post-transcriptional regulatory element is the WPRE.
44. The vector according to 36 wherein said nucleic acid molecule to be expressed encodes a therapeutic protein or peptide.
45. The vector according to claim 44 wherein said therapeutic protein or peptide is selected from the group consisting of: antigen, Cas9, Cas9n, hSpCas9, hSpCas9n, HSVtk, a cell death trigger protein, cholera toxin, diphtheria toxin, alpha toxin, anthrax toxin, exotoxin, pertussis toxin, shiga toxin, shiga-like toxin Fas, TNF, caspases, initiator caspases, caspase 2, 8, 9, 10, 11, 12, and effector caspases, caspase 3, 6, 7 and purine nucleoside phosphorylase. (antigen disclosed on page 18, lines 28-31)
46. The vector according to 36 wherein said expressed nucleic acid molecule is a therapeutic nucleic acid molecule.
47. The vector according to claim 46 wherein said therapeutic nucleic acid is selected from the group consisting of: a microRNA, a siRNA or shRNA, an antisense RNA oligonucleotide, an antisense miRNA, a trans-splicing RNA, a guide RNA, single-guide RNA, crRNA, or tracrRNA, a trans-splicing RNA, a pre-mRNA or mRNA, hsa-mir-30 stem, hsa-mir-125b, and hsa-mir-21. (microRNA disclosed in Example 2, page 45; hsa-mir-30 stem disclosed on page 20, line 25-26; hsa-mir-125b disclosed on page 22, description of
48. A pharmaceutical composition comprising a dumbbell-shaped vector according to claim 36.
49. A method to generate a dumbbell-shaped vector substantially free of bacterial nucleotide sequences comprising: i) providing a preparation comprising a first single stranded nucleic acid template comprising a target nucleic acid molecule comprising a nucleotide sequence of interest; ii) contacting said first single stranded nucleic acid template with an first oligonucleotide primer comprising a 5-phosphate and a 3-hydroxyl group that is complementary to at least part of the 3 terminal nucleotide sequence of said single stranded nucleic acid template and further comprising a 5 nucleotide sequence not complementary to the target nucleic acid molecule wherein said oligonucleotide primer comprises a modified nucleotide sequence that prevents extension of the 5 nucleotide sequence not complementary to the target nucleic acid molecule; iii) providing polymerase chain reaction components and primer extending the 3 annealed oligonucleotide primer to form a second template; iv) contacting said second template with a second oligonucleotide primer comprising a 5-phosphate and a 3-hydroxyl group that is complementary to at least part of the 3 terminal nucleotide sequence of said second template and further comprising a 5 nucleotide sequence not complementary to the second template wherein said oligonucleotide primer comprises a modified nucleotide sequence that prevents extension of the 5 nucleotide sequence not complementary to the second template; v) providing polymerase chain reaction components and primer extending the 3 annealed oligonucleotide primer to form a double stranded nucleic acid; vi) polymerase chain amplify the double stranded nucleic acid to synthesize a pool of template DNA and annealing said templates to create double stranded nucleic acid comprising a 5 nucleotide sequence not complementary to the target nucleic acid molecule; and vii) contacting the annealed template nucleic acid with a DNA ligase to link the terminal 5-phosphate of the non-complementary 5 nucleotide sequence to the 3-OH of said amplified template nucleic acid to create a terminal loop structure.
50. The method according to claim 49 wherein said oligonucleotide primer comprises a nucleotide sequence that is non-complementary with said target nucleic acid molecule but includes a region of internal complementarity over part of its length that forms a stem loop structure.
51. The method according to claim 50 wherein said oligonucleotide primer includes a palindromic nucleotide sequence over part of its length as a modification.
52. The method according to claim 51 wherein said oligonucleotide primer modification is the inclusion of an abasic site in said primer.
53. The method according to claim 52 wherein said abasic site is an apurinic/apyrimidinic site, for example a tetrahydrofuran.
54. The method according to claim 49 wherein said abasic site separates the region complementary to the 3 terminal nucleotide sequence of said single stranded nucleic acid template and the 5 nucleotide sequence not complementary to the target nucleic acid molecule.
55. The method according to 49 said DNA ligase is a phage DNA ligase or a circligase.
Description
[0140] An embodiment of the invention will now be described by example only and with reference to the following figures:
[0141]
[0142]
[0143]
[0144]
[0145]
[0146]
[0147]
[0148]
[0149]
[0150]
[0151]
[0152]
[0153]
[0154]
[0155]
[0156]
[0157]
[0158] Internal loops generated by hairpin-gap-primer PCR trigger increased flexibility of dumbbell ends. B, Rigid dumbbells might enter the NPCs only when approaching them in nearly perpendicular orientation to the nuclear membrane. C, The more flexible ends of the gpPCR-dumbbells could facilitate dumbbell entry into the NPCs even from more oblique angles. D, Dumbbells harbouring small loop might freely pass through the medium-sized NPC channels; however, larger loops may enlarge the DNA effective diameter beyond the cut-off value for passage through midsize NPC meshes, forcing them to enter the nucleus via the much less abundant larger channels;
[0159]
[0160]
[0161]
[0162]
[0163]
[0164]
TABLE-US-00001 TABLE 1 Calculation of costs, excluding those for column purification, for the production of 1 ?g dumbbell DNA based on local prices in Singapore converted into USD. ELAN Nicking enzyme AP1-hp AP1-hp (exo-) AP3-hp AP1-loop db Db Db db db db Oligodeoxyribonucleotides FwP: 330 1st round PCR 5P-FwP: 65 5P-FwP: 65 5P-FwP: 94 5P-FwP: 94 (pmol) RvP: 110 FwP: 5.6 5P-RvP: 22 5P-RvP: 22 5P-RvP: 31 5P-RvP: 31 Loop1: 70 RvP: 5.6 Loop2: 70 2nd round PCR FwP: 70 RvP: 70 DNA polymerase Pfu: 11 1st round PCR Pfu: 2.2 Pfu: 2.2 Pfu: 3.1 Pfu: 3.1 (units) Taq: 22 Taq: 0.7 Taq: 4.4 Taq: 4.4 Taq: 6.3 Taq: 6.3 2nd round PCR Taq: 8.8 Restriction endonuclease XhoI: 9.7 NB. Bpu 10I: 8.8 (units) EcoRI: 9.7 SalI: 4.2 MfeI: 4.2 DNA ligase T4 DNA ligase: T4 DNA ligase: T4 DNA ligase: T4 DNA ligase: T4 DNA ligase: CircLigase: (units) 28 17.5 10.9 10.9 31.3 555 T7 DNA polymerase 28 17.5 10.9 15.6 13.3 (units) Total expenses.sup.[a] 72.5 21.1 13.2 7.0 23.8 211.1 (USD)
SEQUENCE LISTING
[0165]
TABLE-US-00002 SEQIDNO1: 5-AGGTCGGGCAGGAAGAGGGCCTATTTCCCATGATTCCTTCATATTTG CATATACGATACAAGGCTGTTAGAGAGATAATTAGAATTAATTTGACTGT AAACACAAAGATATTAGTACAAAATACGTGACGTAGAAAGTAATAATTTC TTGGGTAGTTTGCAGTTTTAAAATTATGTTTTAAAATGGACTATCATATG CTTACCGTAACTTGAAAGTATTTCGATTTCTTGGCTTTATATATCTTGTG GAAAGGACGAAACACC-3 SEQIDNO2: 5-AATTCGAACGCTGACGTCATCAACCCGCTCCAAGGAATCGCGGGCCC AGTGTCACTAGGCGGGAACACCCAGCGCGCGTGCGCCCTGGCAGGAAGAT GGCTGTGAGGGACAGGGGAGTGGCGCCCTGCAATATTTGCATGTCGCTAT GTGTTCTGGGAAATCACCATAAACGTGAAATGTCTTTGGATTTGGGAATC TTATAAGTTCTGTATGAGACCACAGATCTAA-3 SEQIDNO3: 5-ATATTTGCATGTCGCTATGTGTTCTGGGAAATCACCATAAACGTGAA ATGTCTTTGGATTTGGGAATCTTATAAGTTCTGTATGAGACCACAGATCT AA-3 SEQIDNO4: 5-ATATTTGCATGTCGCTATGTGTTCTGGGAAATCACCATAAACGTGAA ATGTCTTTGGATTTGGGAATCTTATAAGTTCTGTATGAGACGGATCTAAA AA-3 SEQIDNO5: 5-GAATTCAAGGTACCAGATCTTAGTTATTAATAGTAATCAATTACGGG GTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGG TAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCA ATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACG TCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAG TGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGG CCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTG GCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTT GGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCA AGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCA ACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGG GCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTGGTTTAGTG AACCGTG-3 SEQIDNO6: 5-TGGTTGCTGACTAATTGAGATGCATGCTTTGCATACTT-3 SEQIDNO7: 5-AGCCTGGGGACTTTCCACACC-3 SEQIDNO8: 5-TGGTTGCTGACTAATTGAGATGCATGCTTTGCATACTTCTGCCTGCT GGGGAGCCTGGGGACTTTCCACACC-3 SEQIDNO9: 5-CGATGGAGCGGAGAATGGGCGGAACTGGGCGGAGTTAGGGGCGGGAT GGGCGGAGTTAGGGGCGGGACTATGGTTGCTGACTAATTGAGATGCATGC TTTGCATACTTCTGCCTGCTGGGGAGCCTGGGGACTTTCCACACCTGGTT GCTGACTAATTGAGATGCATGCTTTGCATACTTCTGCCTGCTGGGGAGCC TGGGGACTTTCCACACCCTAACTGACACACATTCCACAGC-3 SEQIDNO10: 5-CAGGTAAGTATCAAGGTTACAAGACAGGTTTAAGGAGACCAATAGAA ACTGGGCTTGTCGAGACAGAGACGACTCTTGCGTTTCTGATAGGCACCTA TTGGTCTTACTGACATCCACTTTGCCTTTCTCTCCACAGG-3 SEQIDNO11 ATAATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTT AACTATGTTGCTCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTT GTATCATGCTATTGCTTCCCGTATGGCTTTCATTTTCTCCTCCTTGTATA AATCCTGGTTGCTGTCTCTTTATGAGGAGTTGTGGCCCGTTGTCAGGCAA CGTGGCGTGGTGTGCACTGTGTTTGCTGACGCAACCCCCACTGGTTGGGG CATTGCCACCACCTGTCAGCTCCTTTCCGGGACTTTCGCTTTCCCCCTCC CTATTGCCACGGCGGAACTCATCGCCGCCTGCCTTGCCCGCTGCTGGACA GGGGCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAATC ATCGTCCTTTCCTTGGCTGCTCGCCTGTGTTGCCACCTGGATTCTGCGCG GGACGTCCTTCTGCTACGTCCCTTCGGCCCTCAATCCAGCGGACCTTCCT TCCCGCGGCCTGCTGCCGGCTCTGCGGCCTCTTCCGCGTCTTCGCCTTCG CCCTCAGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGCATC
[0166] Primers and enzymes
[0167] Primers for cloning of plasmids. Oligodeoxyribonucleotides shR-luc-plus 5-GATCCGAGCTGTTTCTGAGGAGCCTTCAAGAGAGGCTCCTCAGAAACAGCTCTTTT TC-3, shR-luc-minus 5-TCGAGAAAAAGAGCTGTTTCTGAGGAGCCTCTCTTGAAGGCTCCTCAGAAACAGCT, shR-gfp-plus 5-GATCCGCTGACCCTGAAGTTCATCTTCAAGAGAGATGAACTTCAGGGTCAGCTTTT TC-3, shR-gfp-minus 5-TCGAGAAAAAGCTGACCCTGAAGTTCATCTCTCTTGAAGATGAACTTCAGGGTCAGCG-3, Fw-SV40 5-ATGCGAGCTCCGATGGAGCGGAGAATGG-3, Rv-SV40 5-ATGCGAATTCGCTGTGGAATGTGTGTCAGTTAGG-3, Fw-pre-miR-125b 5-ATCGTCAGATCTTGCGCTCCTCTCAGTCCC-3, Rv-pre-miR-125b 5-ATCGATAAGCTTTAAAAAAGCACGACTCGCAGCTCC-3, BD-miR-125b-plus 5-pTCACAAGTTAGGGTCTCAGGGAATCACAAGTTAGGGTCTCAGGGAATCACAAGTTAGG GTCTCAGGGA-3, BD-miR-125b-minus 5-pAGCTTCCCTGAGACCCTAACTTGTGATTCCCTGAGACCCTAACTTGTGATTCCCTGAG ACCCTAACTTGTGAAGCT-3, BD-miR-21-plus 5-pTCAACATCAGTCTGATAAGCTAATCAACATCAGTCTGATAAGCTAATCAACATCAGTCT GATAAGCTA-3, and BD-miR-21-minus 5-pAGCTTAGCTTATCAGACTGATGTTGATTAGCTTATCAGACTGATGTTGATTAGCTTATC AGACTGATGTTGAAGCT-3 were synthesized by AITbiotech (Singapore).
[0168] Primers for db Production.
[0169] gpPCR method. Unmodified oligodeoxyribonucleotides Fw-luc 5-TAGAATTCATATTTGCATGTCGCTATGT-3, and Rv-luc 5-AACTCGAGAAAAAGAGCTGTTTCTGAG-3 were synthesized by AITbiotech (Singapore). dSpacer1 (AP1) oligodeoxyribonucleotides Fw-AP1-sh 5-pATCCAGTTTTCTGGA-AP1-TAGAATTCATATTTGCATGTCGCTATGT-3, Rv-AP1-sh 5-pAAGGTCTTTTGACCT-AP1-AACTCGAGAAAAAGAGCTGTTTCTGAG-3, Fw-AP 1-loop 5-pATCCAGTTTTCAGCA-AP 1-TAGAATTCATATTTGCATGTCGCTATGT-3, Rv-AP 1-loop 5-pAAGGTCTTTTCAGCA-AP 1-AACTCGAGAAAAAGAGCTGTTTCTGAG-3 and dSpacer3 (AP3) oligodeoxyribonucleotides Fw-AP3-sh 5-pATCTCCAGTTTTCTGGA-AP3-TAGAATTCATATTTGCATGTCGCTATGT-3, Rv-AP3-sh 5-pATCAGGTCTTTTGACCT-AP3-AACTCGAGAAAAAGAGCTGTTTCTGAG-3, Fw-AP3-loop 5-pATCTCCAGTTTTCAGCA-AP3-TAGAATTCATATTTGCATGTCGCTATGT-3, Rv-AP3-loop 5-pATCTCCAGTTTTCAGCA-AP3-AACTCGAGAAAAAGAGCTGTTTCTGAG-3 and PEG-150 (S9) oligodeoxyribonucleotides Fw-S9-sh 5-pATCGTCCAGTTTTCTGGA-S9-TAGAATTCATATTTGCATGTCGCTATGT-3, Rv-S9-sh 5-pATCGAGGTCTTTTGACCT-S9-AACTCGAGAAAAAGAGCTGTTTCTGAG-3, Fw-59-loop 5-pATCGTCCAGTTTTCAGCA-S9-TAGAATTCATATTTGCATGTCGCTATGT-3, Rv-59-loop 5-pATCGAGGTCTTTTCAGCA-S9-AACTCGAGAAAAAGAGCTGTTTCTGAG-3 oligodeoxyribonucleotides were synthesized by Integrated DNA Technologies (Coralville, USA).
[0170] Generation of hairpin template-transcribing dumbbells. Fw-Bpu-mH1 5-pTTAGGAGTTTTCTCCTAAGCATATTTGCATGTCGCTATGTGTTCTG-3, Rv-BamHI-mH1-pA 5-TGCAGGATCCCTTTTTTCTCATACAGAACTTATAAGATTCCC-3, neutralizing oligonucleotide 5-TTAGGAGTTTTCTCCTAA-3, hp-s/as, 5-pGATCTAAAAAGAGCTGTTTCTGAGGAGCCTCTCTTGAAGGCTCCTCAGAAACAGCTCTTTTTA-3, hp-miR-s/as, 5-pGATCCAAAAATCTTCTCAGTAGGCAAAGAGCTGTTTCTGAGGAGCCTCTCTTGAAGGCTCCTCA GAAACAGCTCCGCGCTCACTGAGAAGATTTTTG-3, hp-iPT-s/as, 5-pGATCTGAGCTGTTTCTGAGGAGCCTCTCTTGAAGGCTCCTCAGAAACAGCTCA-3, hp-iPT-as/s, 5-pTCGACAGG CTCCTCAGAAACAG CTCTCTCTTGAAGAG CTGTTTCTGAGGAG CCTG-3, hp-125b 5-pGATCTAAAAAAGCACGACTCGCAGCTCCCAAGAGCCTAACCCGTGGATTTAAACGGTA AACATCACAAGTTAGGGTCTCAGGGACTGAGAGGAGCGCATTTTTA-3 were synthesized by AITbiotech (Singapore).
[0171] nicking enzyme and ELAN method. Fw-shGFP 5-TTAGGAGTTTTCTCCTAAGCGAATTCATATTTGCATGTCGCTATGT-3, Rv-shGFP 5-TTAGGTCTTTTGACCTAAGCCTCGAGAAAAAGCTGACCCTGAA-3, Fw-linear 5-TTAGGAGTTTTCTCCTAAGCCTAGAACTAGTGGATCCCCGGG-3, Rv-linear 5-TTAGGTCTTTTGACCTAAGCCTCGAGGTCGACGGTATCGA-3, Fw-2.sup.nd 5-pTTAGGAGTTTTCTCCTAAGC-3 and Rv-2.sup.nd 5-pTTAGGTCTTTTGACCTAAGC-3, Rv-21-A1 5-pTTAGGTCTTTTGACCTAAGCAAAAAAGACTGATGTTGACTGTTGAATCTCATGGCAGG GAAAGAGTGGTCTCATACAGAACT-3, Rv-21-A2 5-pTTAGGTCTTTTGACCTAAGCAAAAAGATGTTGACTGTTGAATCTCATGGCAACACCGG GAAAGAGTGGTCTCATACAGAACT-3 Rv-21-A3 5-pTTAGGTCTTTTGACCTAAGCAAAAACGGGTAGCTTATCAGACTGATGTTGACTGTTGAA TGGGAA-3, Rv-21-A4 5-pTTAGGTCTTTTGACCTAAGCAAAAACTGATGTTGACTGTTGAATCTCATGGCAACACCA GGGGAAAGAGTGGTCTCATACAGAACT-3 and loop-primers for the ELAN method L1 5-AATTGTCCAGTTTTCTGGAC-3 and L2 5-TCGACAGGTCTTTTGACCTG-3 were synthesized by AITbiotech.
[0172] Primers and probes for qPCR detection were synthesised by AITbiotech. Stem-loop primer for reverse transcription of the luciferase-targeting shRNA was 5-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACAAGAGC-3, universal Taqman probe was FAM-5-TCGCACTGGATACG-3-MGB, qPCR forward primer for shlucRNA was 5-GAGCTGTTTCTGAGGAGCCTTC-3, qPCR universal reverse primer for shlucRNA was 5-GTGCAGGGTCCGAGGT-3. Taqman probe for mH1 promoter was FAM-5-TCTGGGAAATCACCATAAA-3-BHQ-1, qPCR forward and reverse primers for mH1 promoter were 5-TTCATATTTGCATGTCGCTATGTG-3 and 5-TCCCAAATCCAAAGACATTTCA-3, respectively. qPCR forward and reverse primers for ?-actin were 5-CTGGCACCCAGCACAATG-3 and 5-GCCGATCCACACGGAGTACT-3, respectively. Trans-splicing hybrid RNA was detected by AFP primers 5-AAGGCATCCCTTCCTGTATGC-3, 5-TTGCTGTGTCCCCGTGATC-3 and probe FAM-5-CCTACAATTCTTCTTTGGGCTGCTCGCT-3-BHQ-1 and HSVtk primers 5-CATCTTGCTGCAAAGCTGAAAA-3, 5-TTGCTGTGTCCCCGTGATC-3 and probe FAM-5-CCCCTGCCATCAACACGCGTC-3-BHQ-1.
[0173] Materials & Methods
[0174] Cell Cultivation and Transfection
[0175] Human HEK293T, HepG2, or CL48 cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM) (Invitrogen) supplemented with 10% v/v heat-inactivated Fetal Bovine Serum (Hyclone) and 1% penicillin-streptomycin solution (Invitrogen). Cells were kept in humidified incubator with 5% CO.sub.2, and were passaged at 80-90% confluence. All transfection assays were performed using Lipofectamine 2000 (Invitrogen) following the manufacturer's recommendations.
[0176] Cloning of Plasmids
[0177] The 227 bp human H1 promoter of the pSuper? (Oligoengine) cloning vector was replaced by the 99 bp minimal H1 (mH1) promoter (5). Therefore, both DNA strands resembling the mH1 sequence were chemically synthesized, annealed, purified, and inserted into the pSuper plasmid using EcoRI and BgIII restriction sites to generate plasmid pSuper-mH1. The expression cassette for a firefly luciferase-targeting small hairpin RNA was cloned into the pSuper-mH1 vector. Therefore, oligodeoxyribonucleotides shR-luc-plus and shR-luc-minus were annealed and inserted into pSuper-mH1 using the BgIII and XhoI restriction sites to generate plasmid pSuper-mH1-shR-luc. Similarly, oligodeoxyribonucleotides shR-gfp-plus and shR-gfp-minus were annealed and inserted into pSuper-mH1 using the BgIII and XhoI restriction sites to generate plasmid pSuper-mH1-shR-gfp.
[0178] To generate the hsa-miR-125b expression plasmid pSuper-mH1-miR-125b, the miR-125b precursor gene was PCR amplified from chemically synthesized oligonucleotide template using primers Fw-pre-miR-125b and Rv-pre-miR-125b and inserted into pSuper-mH1 using the BgIII and HindIII sites. The 72 bp minimal SV40 enhancer sequence was synthesized by gene synthesis (GeneArt/Applied Biosystems, Regensburg) and the 237 bp full-length SV40 enhancer was amplified by PCR form plasmid pGL3-Control (Promega, Madison, Wis.) using primers Fw-SV40 and Rv-SV40. Both enhancers were cloned into pSuper-mH1-miR-125b using the SacI and EcoRI sites to generate plasmids pSuper-mH1-miR-125b-mEnh and pSuper-mH1-miR-125b-fEnh. To generate hsa-miR-125b and hsa-miR-21 luciferase reporter sensor plasmids, DNA sequences resembling three tandem repeats of the respective fully complementary miRNA binding sites BD-miR-125b-plus, BD-miR-125b-minus, BD-miR-21-plus and BD-miR-21-minus were chemically synthesized and inserted into pMIR-Report (Promega, Madison, Wis.) using the SacI and HindIII sites.
[0179] Firefly luciferase expression vectors were generated from plasmid pGL3-Control (Promega, Madison, Wis.) which also harbours the full length SV40 enhancer. The 132 bp chimeric human ?-globin mini-intron was synthesized by gene synthesis (GeneArt/Applied Biosystems, Regensburg) and inserted into pGL3-Control using the HindIII and NcoI sites to generate plasmid p-int-luc-enh. SV40 enhancer-negative plasmids p-luc or p-int-luc were generated from plasmids pGL3-Control or p-int-luc-enh by deleting the SV40 enhancer. Therefore these plasmids were cleaved with XbaI and BamHI and the vector backbones were ligated.
[0180] Taq DNA polymerase, pfu DNA polymerase, restriction enzymes, T4 DNA ligase, and T7 DNA polymerase, if not specified otherwise, were purchased from Life technologies (Singapore).
[0181] Dumbbell Vector Generation
[0182] gpPCR method. To generate the template for gap-primer PCR, pSuper-mH1-shR-luc was cleaved with restriction endonucleases KpnI and BamHI. Gap-primer PCR (gpPCR) was performed in a volume of 400 ?l using 400 ng pSuper-mH1-shR-luc/KpnI/BamHI template, 0.2 mM of each dNTP, 0.3 ?M of forward primer, 0.1 ?M reverse primer, and mixture containing 8 U Taq DNA polymerase and 4 U Pfu DNA polymerase. PCR cycling was done as follows: initial denaturing at 95? C. (3 min), then 30 cycles of denaturing at 95? C. (30 s), primer annealing at 53? C. (hp-primers) or 66? C. (loop-primers) (30 s), and extension at 72? C. (30 s), and final extension at 72? C. (5 min). gpPCR products were converted into dumbbells by ligation. All the PCR products were purified by QIAquick PCR Purification Kit (Qiagen). Each 1 ?g of gpPCR product was ligated as follows: AP1-hp products using 10 U T4 DNA ligase (Fermentas), AP3-hp with 20 U T4 DNA ligase, and AP1-loop products with 417 U CircLigase (Epicentre). Ligation with T4 DNA ligase was performed for 15 h at 22? C., ligation with CircLigase for 4 h at 60? C. For exonuclease treatment, 10 U T7 DNA polymerase was added per pg PCR product and the reaction was incubated for 30 min at 37? C.
[0183] Generation of hairpin template-transcribing dumbbells. To produce hairpin template-transcribing db-vectors, the minimal human H1 promoter (mH1) was PCR amplified using pSuper-mH1-shR-luc template, 5-phosphorylated primer Fw-Bpu-mH1 introducing a Nb.Bpu10I site and primer Rv-BamHI-mH1-pA introducing a BamHI site at 5 and 3 end, respectively. The PCR product was then cleaved using Nb.Bpu10I and BamHI and incubated at 37? C. for 4 hrs to release the oligonucleotide resulting from Nb.Bpu10I cleavage in the presence of neutralizing oligonucleotide to avoid reannealing before oligonucleotides were removed using a PCR purification kit (QIAgen). T4 DNA ligase was used to ligate the phosphorylated Nb.Bpu10I 5-overhang to the recessive 3-hydroxyl group to form one loop of the dumbbell and to ligate a 5 phosphorylated DNA hairpin structure comprising a BgIII overhang to the compatible BamHI sticky end to covalently close the dumbbell from the other side. DNA hairpin hp-s/as, hp-miR-s/as, hp-iPT-s/as, hp-iPT-as/s, hp-125b were used to generate db-iPR-hp-s/as, db-iPR-miR-hp-s/as, db-iPTR-hp-s/as, db-iPTR-hp-as/s, and db-hairpin-miR-125b, respectively. Ligation was performed in the presence of BamHI and BgIII to suppress the formation of alternative dumbbells. Resulting dumbbells were subjected to T7 DNA polymerase (Fermentas, Thermo Scientific) treatment to destroy unligated and misligated by-products.
[0184] Nicking enzyme method. For nicking-enzyme-based production we followed the protocol described by Taki et al. performing two rounds of PCR (6,7). Linear shRNA- (egfp- and luciferase-targeting), miRNA-, and miRNA-21 antagonist-expressing dumbbells were produced using this method. To produce the egfp-targeting dumbbell db-Nick, luciferase-targeting shRNA expressing dumbbell db-iPR-linear-s/as, or the miR-125b-1-expressing dumbbell db-linear-miR-125b, double-digested pSuper-mH1-shR-GFP, pSuper-mH1-shR-luc, or pSuper-mH1-miR-125b plasmid was used as the PCR template, respectively, the sequences of forward and reverse primers for the first PCR reaction were Fw-shGFP and Rv-shGFP for db-Nick, Fw-linear and Rv-linear for db-iPR-linear-s/as and db-linear-miR-125b. The sense and antisense primer sequences for the second PCR reaction were Fw-2.sup.nd and Rv-2.sup.nd, respectively.
[0185] To produce the miR-21-targeting miR-21 antagonist-expressing dumbbells db-anti-miR-21-A1/2/3/4, mH1 promoter was amplified using primers Fw-Bpu-mH1 and Rv-21-A1/Rv-21-A2/Rv-21-A3/Rv-21-A4. The miR-21 antagonist sequences were introduced by the reverse primers used. Exonuclease treatment was done as described above.
[0186] ELAN method. For ELAN-based production of dumbbell db-ELAN we followed the protocol by Cost et al. (8). 2000 ng PCR product was digested with each 2 U FD XhoI and FD EcoRI and each 25 pmol of the loop-sequences L1 and L2 were ligated using 10 U of T4 DNA ligase in the presence of 0.5 U of FD XhoI, FD EcoRI, FD SaII, and FD MfeI. Exonuclease treatment was done as described above.
[0187] Knockdown Assay
[0188] To monitor firefly luciferase target gene knockdown, HEK293T cells were co-transfected with luciferase reporter vector pGL3 (Promega) or the respective miRNA-sensor vectors and the respective small RNA expressing dumbbell or plasmid. To investigate gpPCR-generated dumbbells, 90 ng luciferase reporter vector pGL3 (Promega) and either 90 ng dumbbell or plasmid DNA (equimass) or 0.5 pmol of dumbbell or plasmid DNA (equimolar; pVAX1 plasmid was used as top-up DNA for dumbbell transfection) using Lipofectamine 2000 (Life Technologies) and luciferase knockdown was monitored 48 h post transfection. To investigate luciferase-targeting shRNA-expressing dumbbells, miR-125b-1-expressing dumbbells, and miR-21 antagonist-expressing dumbbells, HEK293T or HepG2 cells seeded in 24-wells were co-transfected with 250 ng reporter or sensor plasmid and specified amounts of dumbbell or plasmid.
[0189] RNA Extraction, Reverse Transcription, and qPCR Detection
[0190] To investigate the kinetics of transcription of the luciferase-targeting shRNA, 5?10.sup.5 cells were transfected with 1 pmol of either a db-vector (linear or hairpin designs) or plasmid pSuper-mH1-shR-Luc. 10 min, 1 h, 6 h, and 24 h post transfection total RNA was isolated using Trizol. (Life Technologies) following the manufacturers protocol and shRNA transcripts were quantified using the universal TaqMan-based RT-PCR protocol (4), and the fold change was determined by ??Ct quantification using ?-actin RNA as an internal standard.
[0191] To compare the efficiency of trans-splicing between plasmid and dumbbell vectors, 2?10.sup.5 HepG2 cells were transfected in equimass and equimolar amounts with the 3ER trans-splicing RNA dumbbell vector overexpressed with AFP mini gene plasmid using Lipofectamine 2000 reagent (Life Technologies). The 3ER trans-splicing RNA plasmid overexpressed with AFP mini gene transfected equimass was used as a comparing control. The total amount of DNA transfected was 1000 ng and empty pVAX1 vector was used to top up to the final concentration (in case of equimolar). RNA was extracted 24 hours post-transfection using RNeasy plus mini kit (Qiagen) following manufacturer's protocol. 500ng of total RNA was converted into cDNA with random primers using SuperScript III Reverse Transcriptase (Life Technologies). For real time RT-PCR, 25 ng of cDNA was amplified using the AFP and HSV-tk primer/probes. The fold change was determined by ??Ct quantification using ?-actin RNA as an internal standard.
[0192] To investigate the transcriptional activity of gpPCR-generated dumbbells, 10.sup.5 HepG2 cells were transfected with 0.25 pmol of dumbbell or plasmid DNA using Lipofectamine 2000. pVAX1 plasmid was used as control as well as a top-up DNA for dumbbell transfection. 24 h post transfection, cells were harvested and total RNA was isolated using Trizol. (Life Technologies) following the manufacturers protocol. Luciferase-targeting shRNA (shluc) was detected using the universal TaqMan-based RT-PCR protocol (4), and the fold change was determined by ??Ct quantification using ?-actin RNA as an internal standard.
[0193] All real-time PCR reactions were performed using 1XTaqMan Universal PCR Master Mix (Applied Biosystems) following the manufacturer's instructions using the 7900HT Fast realtime PCR system (Applied Biosystems).
[0194] Nuclear Import Assay
[0195] To investigate the nuclear import of different vectors, 5?10.sup.5 HepG2 cells were seeded in 6-well plates and transfected with 1 pmol of dumbbell or plasmid DNA using Lipofectamine 2000. pVAX1 plasmid was used as control as well as a top-up DNA for dumbbell transfection. 24 h post transfection, cells were harvested, washed twice with cold PBS, incubated in hypotonic buffer (20 mM Tris-Cl, pH 7.4, 10 mM NaCl, 3 mM MgCl.sub.2) for 15 min on ice, and lysed by 20 times dounce homogenization in hypotonic buffer. After centrifugation at 3,000 rpm for 10 min at 4? C., the supernatant (cytoplasmic fraction) was subsequently removed and the pellet (nuclear fraction) was further lysed by four freeze-thaw cycles using liquid nitrogen and a water bath. Lysed nuclei were centrifuged for 30 min at the maximum speed at 4? C. Total nuclear nucleic acids were extracted from the supernatant using Trizol and the absolute abundance of transfected vector DNA was determined by TaqMan qPCR quantification of the copy number of the minimal H1 promoter sequence using the 7900HT Fast realtime PCR system (Applied Biosystems). For qPCR quantification, respective rtPCR standard curves were used to measure db-AP1-hp, db-ELAN, and the supercoiled plasmid DNA.
[0196] Capillary Gel Electrophoresis
[0197] High-resolution capillary electrophoresis was performed using a QIAxcel? DNA high-resolution gel cartridge (Qiagen) on a QIAxcel system (Qiagen) according to the manufacturer's instructions. QX DNA Size Marker pUC18/HaeIII (Qiagen) was used to determine dumbbell vector size using 5 ng/?l QX Alignment Marker 15 bp/1 kb (Qiagen) as internal standard. The OL800 method was used for analysis.
[0198] Multiple Cloning Site Insertion Into CRISPR Plasmids
[0199] This study used the pX330-U6-Chimeric_BB-CBh-hSpCas9 (pX330; Addgene plasmid #42330) and the pX335-U6-Chimeric_BB-CBh-hSpCas9n(D10A) (pX335; Addgene plasmid #42335) plasmids (9) as expression platforms for the type II CRISPR gene editing system. pX330 encodes the type II CRISPR system with wild-type Cas9, while pX335 encodes the type II CRISPR system with the ?HNH Cas9 nickase (Cas9n), which carries the D10A amino acid change.
[0200] To facilitate dumbbell vector construction from pX330 and pX335, suitable restriction sites were required which separate the necessary components, such as the Cas9/Cas9n and sgRNA expression cassettes, from the components which would be excluded from the dumbbell vectors, such as the ampicillin resistance gene and long non-coding regions on the plasmid backbone. Existing restriction sites on pX330 and pX335 were assessed based on restriction enzyme availability, and the compatibility of their sticky ends for dumbbell loop ligation. Due to the absence of suitable restriction sites, a multiple cloning site bearing the XhoI, NheI and HindIII restriction sites was inserted into the existing PscI restriction site on pX330 and pX335. To introduce this multiple cloning site, an equimolar mixture of a pair of single-stranded DNA oligonucleotides (ssODN) (sense: 5-CATGCTCGAGGCTAGCAAGCTT-3; antisense: 5-CATGAAGCTTGCTAGCCTCGAG-3) was annealed by incubation at 95? C. for 5 min, then placed on the bench to cool gradually to room temperature. 5-OH phosphorylation was carried out using T4 Polynucleotide Kinase (PNK) (Thermo Scientific), to give a double-stranded DNA fragment with the respective restriction sites as well as PscI sticky ends. The pX330 and pX335 plasmids were digested with PscI (PciI) (Thermo Scientific), and the fragment ligated with T4 DNA Ligase (Thermo Scientific). The same approach was then used to introduce a second multiple cloning site bearing the BamHI, BsrGI and MluI restriction sites (ssODNs: sense: 5-GGCCACGCGTTGTACAGGATCC-3; antisense: 5-GGCCGGATCCTGTACAACGCGT-3) into the existing NotI restriction site on pX330 and pX335.
[0201] Ligation products were used to transform chemically competent Escherichia coli strain DH5?. Cryostocks (?80? C.) of E. coli DH5? were thawed on ice, and added to 1.5 mL microcentrifuge tubes containing 10 ?L of ligation product using pre-cooled pipette tips. Tubes were kept on ice for one hour, then subjected to heat shock at 42? C. for 90 seconds, and then immediately returned to ice for five minutes. To each tube, 1 mL of LB broth was added and tubes incubated at 37? C. for one hour with shaking. Bacteria were pelleted at 3,000 rpm and resuspended in 50 ?L of LB broth. Suspensions were plated on LB agar plates with 100 ?g/mL ampicillin and incubated overnight at 37? C. Viable transformants were screened for successful multiple cloning site insertion using colony PCR with recombinant Taq DNA polymerase (Thermo Scientific) and capillary electrophoresis sequencing (AITbiotech).
[0202] Design and Sub-Cloning of Guide Sequences
[0203] Possible gRNA target sites terminate in a protospacer adjacent motif (PAM) sequence. The S. pyogenes-derived CRISPR system used in this study recognizes target sites terminating in 5-NGG-3 PAMs (beginning in 5-CCN-3 for targets on the antisense strand) (9). Four candidate 20-nucleotide genomic target sites terminating in NGG or beginning with CCN were identified in close proximity to (within 50 bases of) the G6PD-Mahidol point mutation on exon 6. A universal negative guide sequence was also designed (adapted from Sigma-Aldrich), which when cloned into the CRISPR expression vectors, would also be transcribed into a sgRNA which folds the appropriate secondary structure and lacks predicted targets in the human genome (based on sequence alignments). This was required as a more suitable negative control as compared to an empty vector, since empty vectors not containing any guide sequence would not be transcribed into appropriately-folded sgRNAs capable of binding the Cas9/Cas9n endonucleases. Empty vectors are therefore unsuitable to control for Cas9/Cas9n activity in the absence of a target-complementary guide sequence.
TABLE-US-00003 TABLE gRNAcandidates,includinguniversalnegative guidesequence.Only20nttarget- complementaryguidesequencesareshown. Guidesequence Target-complementarysequence 4 5-TACCCCCTTGAACCCCTCTT-3 16 5-GATGCGGTTCCAGCTTCTGC-3 17 5-TCCGGGCTCCCAGCAGAAGC-3 20 5-CTCTGCAGGTCCCTCCCGAA-3 Universalnegative 5-CGCTACCAGAGCTAACTCA-3
[0204] Guide sequence and their respective complementary (antisense) ssODNs were designed with 5-CACCGN . . . N-3 and 3-CN . . . NCAAA-5 ends respectively to give rise to 5-CACC and 5-AAAC overhangs to facilitate cloning into the existing BbsI restriction site of pX330 and pX335. Equimolar mixtures of guide and complementary ssODNs were annealed and phosphorylated with T4 PNK (Thermo Scientific). pX330-MCS and pX335-MCS plasmids were digested with FastDigest BbsI (Thermo Scientific), generating compatible overhangs for guide sequence ligation, then dephosphorylated with FastAP (Thermo Scientific). Ligation was carried out at 22? C. for 4 hours in 20 ?L reaction mixtures containing 1 U of T4 DNA Ligase (Thermo Scientific), and the insert and vector at a 5:1 molar ratio.
[0205] 10 ?L of each ligation product was used to transform chemically competent E. coli strain DH5?, plated on LB agar plates with 100 ?g/mL ampicillin and incubated overnight at 37? C., and viable colonies subject to colony PCR screening. Colony PCR was performed with 0.5 ?M of a universal forward primer binding a region on the U6 promoter (5-CGATACAAGGCTGTTAGAGAGATAATGG-3), and 0.5 ?M of the respective guide sequence antisense ssODNs as reverse primers. PCR conditions were as follows: 95? C., 10 min; 27 cycles of 95? C. 30 sec, 54? C. 30 sec, 72? C. 1 min; and final extension at 72? C. for 10 min. Colony PCR products were analyzed on 1% agarose gel stained with ethidium bromide.
[0206] Generation of Donor Template Oligonucleotides
[0207] Two G6PD wild-type donors were generated, one with approximately 50-nucleotide homology arms flanking the site of editing (short donor), and another with approximately 200-nucleotide homology arms (long donor). The donors were generated using high-fidelity PCR amplification from genomic DNA of cells from a healthy individual, using 1 U of Pfu DNA polymerase (Thermo Scientific) and 0.5 ?M of each primer (short donor forward primer: 5-TGCAGCTCTGATCCTCACTCC-3; short donor reverse primer: 5-TGGACAGCCGGTCAGAGC-3; long donor forward primer: 5-AAAAGGACGCGTGCCAGCAATGCCACCC-3; long donor reverse primer: 5-AATATTGGATCCGGCTCCTGAGTACCACC-3) under the following conditions: 95? C., 5 min; 30 cycles of 95? C. 30 sec, 55? C. 30 sec, 72? C. 1 min; and final extension at 72? C. for 7 min. Capillary electrophoresis sequencing (AITbiotech) was used to ensure that the donors carried segments of the wild-type sequence.
[0208] A G6PD-Mahidol donor (mutant donor'), bearing the G6PD-Mahidol point mutation, was generated using primer extension site-directed mutagenesis, using the wild-type short donor as a template and a pair of mutagenic primers bearing the mutation close to their 5 ends (Mutagenesis primer 1: 5-TCCAGCTTCTGCTGGGAGC-3; mutagenesis primer 2: 5-GAAGCTGGAACCGCATCATC-3; mutation site in bold). In the first PCR, mutagenesis primer 1 was paired with the short donor forward primer, and mutagenesis primer 2 with the short donor reverse primer. PCR was performed using 0.5 U of Taq DNA polymerase (Thermo Scientific) and 0.5 ?M of each primer, under the following conditions: 95? C., 5 min; 25 cycles of 95? C. 30 sec, 55? C. 30 sec, 72? C. 45 sec; and final extension at 72? C. for 10 min. The 75 bp bands on 1% agarose gel were excised and extracted using a GeneJET Gel Extraction Kit (Thermo Scientific). Both fragments were added to a single, second PCR mixture containing 1 U Pfu DNA polymerase (Thermo Scientific) and 0.5 ?M each of the short donor primer pair, to generate the mutant donor. The reaction mixture was first incubated on a heat block at 95? C. for 5 min, then placed on the bench to cool to room temperature. Once cooled, the mixture was returned immediately to the heat block at 72? C. and incubated for 1 min, then placed into the thermal cycler configured as such: 30 cycles of 95? C. 30 sec, 55? C. 30 sec, 72? C. 30 sec; and final extension at 72? C. for 7 min. An aliquot of the PCR product was analyzed on 1% agarose gel stained with ethidium bromide. Capillary electrophoresis sequencing (AITbiotech) was used to verify successful site-directed mutagenesis of the donor.
[0209] Production of Minimal-Sized CRISPR Dumbbell Vectors by ELAN Loop Ligation
[0210] Dumbbell vectors were generated from the pX330-MCS and pX335-MCS plasmids carrying the guide sequences, using the enzymatic ligation assisted by nucleases (ELAN) method (4,7). The XhoI and MluI sites contained within the introduced multiple cloning sites were chosen to be the termini of the main double-stranded component of the dumbbells. ssODNs were designed with base sequences thermodynamically favouring the formation of hairpin loops. After hairpin formation, the loops would leave SaII (G/TCGAC) and SgsI (AscI) (GG/CGCGCC) 5 overhangs, which were compatible for ligation to the XhoI (C/TCGAG) and MluI (A/CGCGT) overhangs from digestion of the pX330-MCS/pX335-MCS plasmids at their multiple cloning sites. Loop ssODN folding predictions were obtained using mfold (10) (
[0211] Statistical Analysis
[0212] Results were shown as mean ?S.E.M when more than one experiments were performed. Unpaired student t-test was used to determine significance when comparing two groups. For the comparison of more than two groups of data, one-way ANOVA with Newman-Keuls post hoc test was used. Prism 5 Graphpad software was used for the statistical analysis. * represents p value<0.05, ** represents p value<0.01, and *** represents p value<0.001.
EXAMPLE 1
Design, Generation, and Cellular Activity of Hairpin-Template Transcribing Dumbbell Vectors for Small RNA Expression
[0213] We investigated dumbbells as a safe and cheap alternative vector system to trigger transient expression of small non-coding RNAs. To capitalise on the fact that db-vectors know no lower size limit, we sought to minimise dumbbells for small RNA expression as much as possible employing three strategies: Firstly, conventional shRNA- or miRNA-expression cassettes consist of a promoter, a linear RNA-coding sequence, and a transcriptional terminator. Since shRNAs and precursor miRNAs (pre-miRNA) form hairpin structures which harbour a significant degree of self-complementarity, linear expression cassettes contain redundant sequences as the sense and antisense portions forming the stem are included in both strands of the DNA duplex. We eliminated such redundant sequences and in the minimised dumbbells, part of the db-DNA structure resembles the structure of the hairpin RNA, i.e. the duplex of the dumbbell forms the stem of the RNA and one of the terminal db-loops codes for the loop of the RNA hairpin (
[0214] We developed a novel protocol for the generation of minimised hairpin template-transcribing db-vectors (
[0215] To investigate different design features of minimised hairpin-template-transcribing dumbbells, HEK293T or HepG2 cells were co-transfected with the pGL3-Control reporter plasmid and equimolar amounts of different luciferase shRNA-expressing dumbbells, and luciferase gene expression was monitored 24 h post transfection. This comparison indicates that the dumbbell equipped with the integrated promoter/terminator/restriction element (db-iPRT-hp-s/as) triggered as strong or better target gene knockdown compared with a construct harbouring separated promoter and terminator sequences (db-iPR-hp-s/as) (
[0216] Earlier studies reported superior delivery and transcriptional activity triggered by db-vectors compared with plasmid DNA (12,13). First-time we investigated in detail the kinetics of cellular and nuclear db-delivery, transcriptional activity, and target gene knockdown triggered by db-driven shRNA expression in comparison with equivalent plasmid vectors. HepG2 cells were co-transfected using lipofectamine 2000 with the firefly luciferase reporter vector pGL3-Control and equimolar amounts of either a conventional db-vector (db-iPR-linear-s/as) harbouring a linear expression cassette, a minimised hairpin template-transcribing dumbbell (db-iPRT-hp-s/as) or a plasmid (p-iPR-linear-s/as), each expressing a mH1 promoter-driven luciferase targeting shRNA (
[0217] At all investigated time points, the kinetics indicate a clear advantage of the dumbbells over the corresponding plasmid in terms of cellular delivery (transfection) and in particular regarding nuclear delivery and shRNA transcription (
[0218] At 10 min post transfection, cellular delivery levels had reached about 6% (plasmid and linear db) or 3% (minimised db) of the 24 h levels, the transcriptional levels about 5/2/8% (plasmid/linear db/minimised db) (
EXAMPLE 2
Design of Hairpin-Template Transcribing Dumbbell Vectors for MicroRNA Expression
[0219] The minimised db-design along with the new protocol for db-generation is applicable for shRNA- and miRNA-expressing dumbbells. We designed a human miR-125b-1 expressing minimised hairpin template-transcribing dumbbell with integrated promoter/restriction/terminator element (db-iPRT-hp-miR) as well as a conventional dumbbell (db-linear-miR) and a plasmid vector (p-linear-miR), the latter each with linear miR-125b-1 expression cassettes (
EXAMPLE 3
[0220] Nuclear DNA Import Sequences Improve Target Gene Knockdown Triggered by Small RNA Expressing Dumbbell Vectors
[0221] Fast passive diffusion from the cytoplasm into the nucleus is regarded to be one of the key features that can be assigned to db-vectors. For larger plasmid DNA it was reported that certain sequences harbouring transcription factor binding sites significantly enhance gene expression. Examples are the SV40 enhancer sequence (17,18), the smooth muscle ?-actin (SMGA) promoter (19,20), and the origin of replication of the Epstein-Barr virus (oriP), the latter of which depends on the expression of the viral nuclear antigen 1 (EBNA1) in order to be functional (21). We investigated whether this strategy is suitable to further improve nuclear import and gene expression of db-vectors. Therefore we implemented either the 237 bp full-length SV40 enhancer (fEnh) or a 72 bp minimal version (mEnh) of it (17) into the minimised miR-125b-1-expressing dumbbell upstream of the mH1 promoter (
EXAMPLE 4
[0222] Design of Antisense miRNA-Expressing Dumbbell Vectors
[0223] As miRNAs are important posttranscriptional regulators of metazoan gene expression, both their overexpression and functional inhibition can be of therapeutic value. Most miRNA antagonists are chemically synthesised oligodeoxyribonucleotides with antisense orientation to the miRNA and/or its precursor (23,24). Alternatively, long miRNA targeting antisense RNAs (miRNA sponges) or siRNAs were described as well. Short endogenously expressed miRNA-targeting antisense RNA (asRNA) has not been described yet. We investigated the possibility to use small db-vectors for antisense miRNA expression. As a target we selected hsa-miR-21 which is overexpressed in the context of hepatocellular carcinoma (25) and designed four antisense miRNA (as-miRNA) structures targeting at the same time the mature miR-21 and part of its precursor (pre-miR-21), thus overlapping with one of the dicer cleavage sites. That is, these as-miRNAs would be suitable to target the primary miR-21 transcript, pre-miR-21, and/or mature miR-21 (
[0224] Our analyses indicate an inverse correlation between the sizes of equally featured naked DNA-based vectors and the kinetics of gene expression. The advantage of the dumbbells over the plasmids was found to be highly evident when delivering equimolar amounts of vector DNA and is expected to become even more pronounced when equimass amounts would be applied. Considering limitations associated with some delivery strategies e.g. with regard to maximally deliverable volumes or toxicity triggered by liposomal or other complexing compounds, together with the fact that the total mass of deliverable DNA is limited, it can be regarded as a strong advantage of the db-vector system that equimass amounts correspond to much higher molar amounts as compared with larger minicircles or plasmids.
[0225] In our in vitro system, small dumbbell size is advantageous mainly in terms of improved nuclear delivery and it remains to be tested whether that goes along with a disproportionate higher risk of nuclear vector integration. In vivo, genetic vectors additionally have to manage extracellular transport including extravasation, diffusion through the extracellular matrix network, target cell binding and internalisation. To overcome these physical including membrane barriers, a small vector size can be highly beneficial. Our data demonstrate that dumbbell vectors trigger accelerated, prolonged, transient small RNA expression. Thus, in terms of small RNA delivery, dumbbell vectors may close the existing gap between short-term knockdown effects triggered by siRNAs or miRNA mimics and long-term effects that can be achieved with integrating lentiviral vectors thereby enabling and facilitating therapeutic applications of this vector system.
EXAMPLE 5
[0226] Design of Dumbbell Vectors for Coding RNA ExpressionA Spliceable Intron and/or the SV40 Enhancer Improve Dumbbell-Driven Gene Expression
[0227] Most db-vectors reported in the literature were designed to express functional proteins and, hence, much larger in size compared with the small RNA expressing dumbbells discussed above. We investigated as to whether the full length SV40 enhancer would be suitable to enhance protein expression driven by large db-vectors. As a second molecular feature to enhance protein expression we implemented a spliceable intron. While the implementation of introns into db-vectors was reported earlier (31), SV40 enhancer elements have not been described in dumbbells yet. Using the ELAN method we generated a db-vector containing a SV40 promoter-driven firefly luciferase gene and the SV40 polyadenylation site (db-luc) as well as variations of this parental vector harbouring either the full-length SV40 enhancer (db-luc-enh), the human 6-globin gene chimeric intron (32) (db-int-luc), or both (db-int-luc-enh) (
EXAMPLE 6
[0228] Design of Trans-Splicing RNA-Expressing Dumbbells
[0229] We explored the possibility of using db-vectors for delivery of RNA trans-splicing into human tissue culture cells and compared the db-based with the plasmid-based delivery approach. Spliceosome-mediated RNA trans-splicing represents an alternative form of splicing that describes the joining of sequences originating from distinct transcripts (33). RNA trans-splicing is increasingly being explored for diagnostic and therapeutic applications as it can be used for genetic repair and reprogramming as well as for labelling of endogenous transcripts with death signals for suicide gene therapy or with fluorescent proteins for gene expression imaging. Our trans-slicing RNA was composed of a 5-terminal antisense binding domain targeting intron 5 of the alpha-fetoprotein pre-mRNA, a splice acceptor site, and a sequence coding for a fusion protein of the P2A proteolytic cleavage site (34) and the herpes simplex virus thymidine kinase (HSVtk). This trans-splicing RNA was capable of tagging the endogenous AFP or an over-expressed AFP mini-gene with the HSVtk message via trans-splicing-based 3-end labelling. Successful trans-splicing leads to the expression of the HSVtk enzyme which can trigger a cell death signal upon delivery of the drug ganciclovir for suicide gene therapy (35-37). HepG2 cells were transfected with equimolar amounts of the trans-splicing RNA-expressing plasmid or db-vector, and total RNA was isolated 24 h post transfection. The efficiency of trans-splicing was monitored by rtRT-PCR-based detection of the resulting chimeric AFP-HSVtk RNA using each one AFP-specific and one HSVtk-specific TaqMan-probe (
EXAMPLE 7
[0230] Gap-Primer PCREfficient Production of Superior Dumbbell-Shaped DNA Minimal Vectors for Small RNA Expression
[0231] To further simplify and cheapen dumbbell production and to increase the yields, we developed a two-step PCR-based method that involves chemically-modified gap-primers (
[0232] We investigated the efficiency of our new method in terms of dumbbell production using first the hp-primers together with T4 DNA Ligase (
[0233] Our results indicate that among the series of hp-primers, only those harbouring tetrahydrofuran-based gaps are suitable to produce dumbbell vectors, with highest yields obtained for the smallest gap AP1. That is, a single abasic site efficiently pauses the polymerase without providing any evidence that the enzyme may jump over the gap. It is reasonable to assume that the larger AP3 gap halts the polymerase as effectively as the shorter AP1 gap. However, AP1-primer ligation likely is more efficient due to the more precise positioning of the 5-end for ligation with the 3-end. Currently the question cannot be answered as to whether TEG-gaps are either skipped by the polymerase yielding double-stranded DNA ends which would be unsuitable for dumbbell formation, or alternatively trigger the formation of substrates which are difficult to ligate.
[0234] Next, we evaluated the dumbbell conversion yields by determining the ratios of dumbbell vector DNA after ligation and exonuclease treatment divided by the PCR product yields prior to enzymatic treatment. Among the hp-primer series, highest conversion yields were obtained with the AP1-hp-primers (92%), followed by the AP3-hp-primers (64%), and no dumbbell DNA was produced with the TEG-hp-primers (
[0235] Dumbbell purity after exonuclease treatment was investigated using PAGE and high-resolution capillary gel electrophoresis (
[0236] We calculated and compared the overall input and expenses for the production of 1 ?g dumbbell DNA produced either with the conventional methods or our new strategy (Table 1). Among all investigated protocols including the different gpPCR protocols, AP1-hp-primers generated the most active dumbbells at highest yields and lowest costs. In comparison, both the ELAN and the nicking enzyme method require more and higher amounts of primers and enzymes. A major cost factor involved with the conventional methods is the need for restriction endonucleases. Though gpPCR depends on modified primers, AP1-hp-primer PCR is 10 or 5-fold cheaper compared with the ELAN method and 3.1 or 1.6-fold cheaper compared with the nicking enzyme method, depending on whether the final exonuclease treatment is skipped or not.
EXAMPLE 8
[0237] Gap-Primer PCR Generated Dumbbells are Superior Compared With Conventionally Produced Dumbbells
[0238] All dumbbell vectors investigated in this study harbour the expression cassette for a pre-validated firefly luciferase targeting small hairpin RNA (shRNA). We tested the functionality of gpPCR-generated dumbbells, i.e. luciferase knockdown in human tissue culture cells, in comparison with a dumbbell produced using the ELAN method or a pSuper-based plasmid vector, all expressing the same shRNA driven by the minimal H1 promoter (
[0239] The gpPCR-generated dumbbells triggered significantly (p<0.001) stronger knockdown compared with the ELAN-produced dumbbell, the latter of which was equal in size and uses the same expression cassette to transcribe the same shRNA. Thus, the only difference between gpPCR- and ELAN-produced dumbbells relies in a) abasic sites that trigger the formation of b) internal loops close to the ends of the gpPCR-generated dumbbells. Abasic sites are being cleaved by the apurinic/apyrimidinic enzyme 1 (APE1) in human cells prior to base excision and/or nucleotide incision repair (
[0240] To prove our hypothesis that gpPCR-dumbbells are more efficiently entering cellular nuclei, HepG2 cells were transfected with equimolar (1 pmol) amounts of db-AP1-hp, db-ELAN, or plasmid DNA and both nuclear vector abundance as well as transcriptional vector activity were monitored 24 h post transfection using qPCR (
[0241] In summary, our novel two-step gpPCR method produces higher yields of superior dumbbells at lower costs within a shorter period of time. The protocol is scalable and may facilitate large-scale production of RNA or protein expressing dumbbell vectors for pre-clinical and clinical investigation towards efficient and safe genetic therapy. The current focus and future challenge lies in covalent linkage of RNA, peptide or protein helper functions to the loops of the dumbbells for targeted delivery in vivo.
EXAMPLE 9
[0242] Dumbbell Vectors Trigger Prolonged Expression of Transgenes in Human Primary Cells
[0243] Many promising approaches in molecular medicine depend on efficient delivery of recombinant DNA into primary cells ex vivo or in vivo in order to trigger the expression of non-coding RNAs or proteins and subsequently a therapeutic phenotype. These approaches include the genetic therapy of inherited and acquired genetic diseases, genetic vaccination, stem cell programming, somatic cell reprogramming, immunotherapy, and protein expression.
[0244] All state-of-the-art technologies harbor major disadvantages: the expression of conventional naked DNA-based vectors such as plasmids is silenced in primary cells within 24 hours after delivery and RNA-based vectors achieve only short-term effects due the kinetic instability of RNA in living cells or organisms. Sustained transgene expression was only achieved with integrating viral delivery vectors, such as retroviral, lentiviral, or AAV vectors, which harbor severe safety concerns and risks. The dumbbell vector-based technology of this invention enables researchers and clinicians to achieve sustained transgene expression in primary cells without the need to integrate the foreign DNA into the host cell genome. In our example we designed and generated dumbbell-shaped DNA vectors for the expression of the eGFP reporter gene (
EXAMPLE 10
Dumbbell Vectors for RNA-Guided Genome Editing
[0245] We designed, generated, and tested dumbbell vectors to deliver the CRISPR/Cas9(n)-mediated RNA-guided genome editing system into human cells for reversal of Glucose-6-phosphate dehydrogenase (G6PD) deficiency.
[0246] RNA-guided genome editing is based on RNA-mediated adaptive defense systems evolved from bacteria and archaea (46-49) termed clustered regulatory interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) systems which originally use short RNAs to direct degradation of foreign invading DNA originating from viruses or plasmids. The most popular system is the Streptococcus pyogenes (SP) type II CRISPR system. For editing of genomic DNA in human cells several system adaptations were made: 1. The originally distinct two short RNA molecules, called CRISPR RNA (crRNA) and trans-activating crRNA (tracrRNA), necessary to guide the enzyme to the DNA target in order to trigger cleavage were fused to form a single guide RNA (gRNA). The scaffolding tracrRNA domain, hereinafter referred to as Cas-interacting domain, can be fused to any crRNA domain, hereinafter referred to as DNA binding domain (BD) (50). 2. Codon optimization converted the SPCas9 into the hSPCas9 (51). 3. To reduce off-target editing, an aspartate-to-alanin substitution (D10A) was introduced to convert the DNA double-strand break (DSB) triggering hSPCas9 into the DNA nickase hSPCas9n (9). The DNA binding domain (20 to 17 nt in length) of the gRNA can now guide the gRNA-Cas9 complex to complementary/homologous DNA sites termed protospacer, hereinafter referred to as DNA target site, which has to be followed 3 by a second short identifier called PAM (protospacer adjacent motif) which is 5-NGG for the system described here. The BD of the gRNA can overlap with the site to be edited, or should alternatively be in proximity to this site. hSPCas9 complexes will then trigger DSBs, hSPCas9n complexes trigger nicks. Two hSPCas9n complexes with different gRNAs and shifted target sites will be required to trigger a double nick. DSBs including double nicks induced by Cas9 or Cas9n will then activate one of two endogenous repair mechanisms: 1. In the error-prone non-homologous end-joining (NHEJ) pathway, the ends will be processed and rejoined which can result in random insertion/deletion (indel) mutations. 2. Alternatively, a repair template in form of a plasmid, PCR product or single-stranded oligodeoxyribonucleotides (termed oligonucleotides in the following) can be supplied to leverage the homology-directed repair (HDR) pathway triggering high fidelity, precise editing. Single nicks trigger HDR using the intact strand as template. Beauty and simplicity of this technology, as opposed to transcription activator-like effector nucleases (TALENs) or zinc-finger nucleases (ZFNs), are given by the facts that (i) genomic target site selection is determined solely by base-complementarity to the gRNA and the optimized enzyme does not require further reengineering, (ii) higher targeting efficiencies (repair rates in the range of up to several ten %), and (iii) the possibility to perform multiplex genome editing (9, 52).
[0247] Red blood cell disorders also termed erythrocytic abnormalities (EAs) are the most prevalent inherited disorders worldwide. In particular, Southeast (SE) Asia bears a considerable burden of heritable EAs, which in most cases adversely affect normal human development and life span. The only cure has been the transplantation of bone-marrow cells (BMCs) from foreign donors whose success depends on the limited availability of suitable donors. Therapies based on genetic correction of a patient's own BMCs using state-of-the-art viral delivery vectors have shown promise, however its clinical application is limited by the alarming possibility of uncontrolled genomic vector integration. Thus there is a pressing need to develop gene therapies that are both safe and efficient. We developed dumbbell-shaped DNA minimal vectors to deliver the CRISPR/Cas9(n) genome editing technology into human tissue culture cells and cord blood stem cells (HSCs) isolated from patients to cure an important SE Asian EA, the Glucose-6-phosphate dehydrogenase deficiency.
[0248] RNA-guided genome editing requires the CRISPR/Cas9(n) components to be expressed for a sufficient but limited period of time. While plasmid vectors are suitable due to rapid transgene silencing in primary cells, lentiviral vectors irreversibly change the host cell genome offside the intended editing site. Dumbbell vectors trigger prolonged gene expression in primary cells and do not interfere with the target cell genome and, hence, are most suitable to deliver RNA-guided genome editing into primary including human primary cells.
[0249] We demonstrated that distinct molecular features can enhance the expression of coding and non-coding genes from db-vectors. We considered these features to design vectors which show strongest expression of hSPCas9(n). The basic dumbbell is composed of the gRNA and hSPCas9(n) expression cassettes of vectors pX330 and pX335 (9), containing the gRNA under control of the human U6 (hU6) promoter, followed by the CBh promoter, an modified MVM intron 3, the hSPCas9(n) coding sequence flanked by two nuclear localization signals, and the bGHpA (bovine growth hormone) polyadenylation signal (
[0250] Dumbbell construct A was generated from corresponding plasmid DNA using an optimized ELAN protocol (
[0251] We performed a cutter assay to investigate the target cleavage activities. Therefore, 293T cells were co-transfected with the pVAX plasmid harbouring the G6PD Mahidol mutation as a target site and equimolar amounts of either a dumbbell vector or the corresponding plasmid expressing different guide-RNAs (g4, g16, g17, and g20). Episomal DNA was isolated and target cleavage was quantified using qPCR (
[0252] Next we measured reversal of the G6PD Mahidol mutation on episomal plasmid target DNA in human tissue culture cells. PCR-RFLP qualitative analysis of episomal DNA extracts revealed successful editing of the G6PD-Mahidol mutation on the pVAX1-Mahidol repair target, to the wild-type sequence in 293T cells after 24 hours (
REFERENCES
[0253] 1. Paul W E (2008). Fundamental Immunology. Philadelphia, Wolters Kluwer/Lippincott Williams & Wilkins. [0254] 2. Murphy K, Travers P, Walport M, Janeway C (2012). Janeway's immunobiology. New York, Garland Science. [0255] 3. Wagner R W, Matteucci M D, Grant D, Huang T, Froehler B C (1996). Potent and selective inhibition of gene expression by an antisense heptanucleotide. Nat Biotechnol 14, 7, 840-4. [0256] 4. Jung U, Jiang X, Kaufmann S H E, Patzel V (2013). A universal stem-loop primer-based TaqMan RT-PCR protocol for cost efficient detection of small non-coding RNA. RNA 19, 1864-73. [0257] 5. Myslinski E, Am? J-C, Krol A, Carbon P (2001). An unusually compact external promoter for RNA polymerase III transcription of the human H1RNA gene. Nucleic Acids Res. 29, 2502-9. [0258] 6. Taki M, Kato Y, Miyagishi M, Takagi Y, Sano M, Taira K (2003). A direct and efficient synthesis method for dumbell-shaped linear DNA using PCR in vitro. Nucleic Acids Res Suppl 3, 191-2. [0259] 7. Taki M, Kato Y, Miyagishi M, Takagi Y, Taira K (2004). Small-interfering-RNA expression in cells based on an efficiently constructed dumbbell-shaped DNA. Angew Chem Int Ed Engl 43, 24, 3160-3. [0260] 8. Cost G J (2007). Enzymatic ligation assisted by nucleases: simultaneous ligation and digestion promote the ordered assembly of DNA. Nat Protoc 2, 9, 2198-202. [0261] 9. Cong L, Ran F A, Cox D, Lin S, Barretto R, Habib N, Hsu P D, Wu X, Jiang W, Marraffini L A, Zhang F (2013). Multiplex genome engineering using CRISPR/Cas systems. Science 339, 6121, 819-23. [0262] 10. Zuker M (2003). Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 31, 13, 3406-15. [0263] 11. Zeng Y, Wagner E J, Cullen B R (2002). Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol Cell 9, 6, 1327-33. [0264] 12. Schakowski F, Gorschluter M, Junghans C, Schroff M, Buttgereit P, Ziske C, Schottker B, Konig-Merediz S A, Sauerbruch T, Wittig B, Schmidt-Wolf I G (2001). A novel minimal-size vector (MIDGE) improves transgene expression in colon carcinoma cells and avoids transfection of undesired DNA. Mol Ther 3, 5 Pt 1, 793-800. [0265] 13. Schakowski F, Gorschluter M, Buttgereit P, Marten A, Lilienfeld-Toal M V, Junghans C, Schroff M, Konig-Merediz S A, Ziske C, Strehl J, Sauerbruch T, Wittig B, Schmidt-Wolf I G (2007). Minimal size MIDGE vectors improve transgene expression in vivo. In Vivo 21, 1, 17-23. [0266] 14. Grimm D, Streetz K L, Jopling C L, Storm T A, Pandey K, Davis C R, Marion P, Salazar F, Kay M A. (2006). Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441, 7092, 537-41. [0267] 15. Liang L, Wong C M, Ying Q, Fan D N, Huang S, Ding J, Yao J, Yan M, Li J, Yao M, Ng I O, He X (2010). MicroRNA-125b suppressesed human liver cancer cell proliferation and metastasis by directly targeting oncogene LIN28B2. Hepatology 52, 5, 1731-40. [0268] 16. Jia H Y, Wang Y X, Yan W T, Li H Y, Tian Y Z, Wang S M, Zhao H L (2012). MicroRNA-125b Functions as a Tumor Suppressor in Hepatocellular Carcinoma Cells. Int J Mol Sci 13, 7, 8762-74. [0269] 17. Dean D A (1997). Import of Plasmid DNA into the Nucleus Is Sequence Specific. Experimental Cell Research 230, 293-302. [0270] 18. Dean D, Dean B, Muller S, Smith L (1999). Sequence Requirements for Plasmid Nuclear Import. Experimental Cell Research 253, 713-22. [0271] 19. Vacik J, Dean B S, Zimmer W E, Dean D A (1999). Cell-specific nuclear import of plasmid DNA. Gene Therapy 6, 1006-14. [0272] 20. Miller A M, Dean D A (2008). Cell-specific nuclear import of plasmid DNA in smooth muscle requires tissue-specific transcription factors and DNA sequences. Gene Ther 15, 15, 1107-15 [0273] 21. L?ngle-Rouault F, Patzel V, Benavente A, Taillez M, Silvestre N, Bompard A, Sczakiel G, Jacobs E, Rittner K (1998). Up to 100-Fold Increase of Apparent Gene Expression in the Presence of Epstein-Barr Virus oriP Sequences and EBNA1: Implications of the Nuclear Import of Plasmids. Journal of Virology 72, 6181-5. [0274] 22. Miller A, Dean D (2009). Tissue-specific and transcription factor-mediated nuclear entry of DNA. Advanced Drug Delivery Reviews 61, 603-13. [0275] 23. Kr?tzfeldt J, Rajewsky N, Braich R, Rajeev K G, Tuschl T, Manoharan M, Stoffel M (2005). Silencing of microRNAs in vivo with antagomirs. Nature 438, 7068, 685-9 [0276] 24. Chabot S, Orio J, Castanier R, Bellard E, Nielsen S J, Golzio M, Teissie J (2012). LNA-based oligonucleotide electrotransfer for miRNA inhibition. Mol Ther 20, 8, 1590-8. [0277] 25. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob S T, Patel T (2007). MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133, 647-58. [0278] 26. Patzel V, Sczakiel G (1998). Theoretical design of antisense RNA structures substantially improves annealing kinetics and efficacy in human cells. Nature Biotechnology 16, 1, 64-8. [0279] 27. Patzel V (2004). In silico design of functional RNA molecules. Curr Opin Drug Discov Dev 7, 3, 360-9. [0280] 28. Patzel V, Sczakiel G (2000). In vitro selection supports the view of a kinetic control of antisense RNA-mediated inhibition of gene expression in mammalian cells. Nucleic Acids Res. 28, 13, 2462-6. [0281] 29. Patzel V, Sczakiel G (1999). Length dependence of RNA-RNA annealing. J. Mol. Biol. 294, 1127-34. [0282] 30. Lehmann M J, Patzel V, Sczakiel G (2000). Theoretical design of antisense genes with statistically increased efficacy. Nucleic Acids Res 28, 13, 2597-604. [0283] 31. Schirmbeck R, Konig-Merediz S A, Riedl P, Kwissa M, Sack F, Schroff M, Junghans C, Reimann J, Wittig B (2001). Priming of immune responses to hepatitis B surface antigen with minimal DNA expression constructs modified with a nuclear localization signal peptide. J Mol Med (Berl) 79, 5-6, 343-50. [0284] 32. Brinster R L, Allen J M, Behringer R R, Gelinas R E, Palmiter R D (1988). Introns increase transcriptional efficiency in transgenic mice. Proc Natl Acad Sci USA 85, 3, 836-40. [0285] 33. Mansfield S G, Chao H, Walsh C E (2004). RNA repair using spliceosome-mediated RNA trans-splicing. Trends Mol Med 10, 6, 263-8. [0286] 34. Kim J H, Lee S R, Li L H, Park H J, Park J H, Lee K Y, Kim M K, Shin B A, Choi S Y (2011). High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice. PLoS One 6, 4, e18556. [0287] 35. Beltinger C, Fulda S, Kammertoens T, Meyer E, Uckert W, Debatin K M (1999). Herpes simplex virus thymidine kinase/ganciclovir-induced apoptosis involves ligand-independent death receptor aggregation and activation of caspases. Proc Natl Acad Sci USA 96, 15, 8699-704. [0288] 36. Jiang Y X, Lu Y, Liu T J, Yang J, Chen Y, Fang Y W (2011). Using HSV-TK/GCV suicide gene therapy to inhibit lens epithelial cell proliferation for treatment of posterior capsular opacification. Mol Vis 17, 291-9. [0289] 37. Hwang H C, Smythe W R, Elshami A A, Kucharczuk J C, Amin K M, Williams J P, Litzky L A, Kaiser L R, Albelda S M (1995). Gene therapy using adenovirus carrying the herpes simplex-thymidine kinase gene to treat in vivo models of human malignant mesothelioma and lung cancer. Am J Respir Cell Mol Biol 13, 1, 7-16. [0290] 38. Rumney S, Kool E T (1995). Structural Optimization of Non-Nucleotide Loop Replacements for Duplex and Triplex DNAs. J. Am. Chem. Soc. 117, 5635-46. [0291] 39. Takeshita M, Chang C N, Johnson F, Will S, Grollman A P (1987). Oligodeoxynucleotides containing synthetic abasic sites. Model substrates for DNA polymerases and apurinic/apyrimidinic endonucleases. J. Biol. Chem. 262, 10171-9. [0292] 40. Lin C, Xie M, Chen J J, Liu Y, Yan H (2006). Rolling-circle amplification of a DNA nanojunction. Angew Chem Int Ed Engl 45, 45, 7537-9. [0293] 41. Chu B C, Orgel L E (1992). The stability of different forms of double-stranded decoy DNA in serum and nuclear extracts. Nucleic Acids Res 20, 21, 5857-8. [0294] 42. Sambrook J, Russell D W (2001). Molecular cloning: a laboratory manual. Cold Spring Harbor, N.Y., Cold Spring Harbor Laboratory Press. [0295] 43. Li M, Wilson D M, 3rd (2014). Human apurinic/apyrimidinic endonuclease 1. Antioxid Redox Signal 20, 4, 678-707. [0296] 44. Mohr D, Frey S, Fischer T, Guttler T, Gorlich D (2009). Characterisation of the passive permeability barrier of nuclear pore complexes. EMBO J 28, 17, 2541-53. [0297] 45. Rybenkov V V, Cozzarelli N R, Vologodskii A V (1993). Probability of DNA knotting and the effective diameter of the DNA double helix. Proc Natl Acad Sci USA 90, 11, 5307-11. [0298] 46. Wiedenheft B, Sternberg S H, Doudna J A (2012). RNA-guided genetic silencing systems in bacteria and archaea. Nature 482, 7385, 331-8. [0299] 47. Horvath P, Barrangou R (2010). CRISPR/Cas, the immune system of bacteria and archaea. Science 327, 5962, 167-70. [0300] 48. Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S, Romero D A, Horvath P (2007). CRISPR provides acquired resistance against viruses in prokaryotes. Science 315, 5819, 1709-12. [0301] 49. Marraffini L A, Sontheimer E J (2008). CRISPR interference limits horizontal gene transfer in staphylococci by targeting DNA. Science 322, 5909, 1843-5. [0302] 50. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna J A, Charpentier E (2012). A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 6096, 816-21. [0303] 51. Ran F A, Hsu P D, Wright J, Agarwala V, Scott D A, Zhang F (2013). Genome engineering using the CRISPR-Cas9 system. Nat Protoc 8, 11, 2281-308. [0304] 52. Mali P, Yang L, Esvelt K M, Aach J, Guell M, DiCarlo J E, Norville J E, Church G M (2013). RNA-guided human genome engineering via Cas9. Science 339, 6121, 823-6. [0305] 53. Niang M, Bei A K, Madnani K G, Pelly S, Dankwa S, Kanjee U, Gunalan K, Amaladoss A, Yeo K P, Bob N S, Malleret B, Duraisingh M T, Preiser P R (2014). STEVOR is a Plasmodium falciparum erythrocyte binding protein that mediates merozoite invasion and rosetting. Cell Host Microbe 16, 1, 81-93.